LeMaitre Vascular (LMAT) Downgraded by ValuEngine

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Friday.

Several other equities research analysts have also commented on the stock. Benchmark upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a research report on Thursday. Stifel Nicolaus lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $40.00 to $34.00 in a research report on Thursday. BidaskClub upgraded shares of LeMaitre Vascular from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, April 3rd. Zacks Investment Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a research report on Wednesday, February 28th. Finally, Canaccord Genuity reiterated a “hold” rating and issued a $33.00 price objective on shares of LeMaitre Vascular in a research report on Friday, February 23rd. Five equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $35.33.

LeMaitre Vascular stock opened at $32.35 on Friday. LeMaitre Vascular has a 52 week low of $25.05 and a 52 week high of $41.28. The stock has a market capitalization of $748.83, a P/E ratio of 37.62, a price-to-earnings-growth ratio of 2.65 and a beta of 0.54.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Wednesday, April 25th. The medical instruments supplier reported $0.19 EPS for the quarter, missing the consensus estimate of $0.21 by ($0.02). LeMaitre Vascular had a return on equity of 16.93% and a net margin of 17.03%. The business had revenue of $25.99 million during the quarter, compared to analysts’ expectations of $26.42 million. During the same quarter in the prior year, the firm earned $0.16 earnings per share. LeMaitre Vascular’s quarterly revenue was up 7.8% on a year-over-year basis. analysts anticipate that LeMaitre Vascular will post 0.98 earnings per share for the current fiscal year.

In other LeMaitre Vascular news, Chairman George W. Lemaitre sold 45,000 shares of the company’s stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $34.66, for a total value of $1,559,700.00. Following the transaction, the chairman now directly owns 3,225,709 shares in the company, valued at approximately $111,803,073.94. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Chairman George W. Lemaitre sold 30,000 shares of the company’s stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $36.19, for a total transaction of $1,085,700.00. Following the completion of the transaction, the chairman now owns 3,180,709 shares in the company, valued at $115,109,858.71. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 137,736 shares of company stock worth $4,866,186. 23.70% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in the business. BB&T Corp acquired a new position in shares of LeMaitre Vascular during the 4th quarter valued at about $202,000. Advisor Group Inc. increased its stake in shares of LeMaitre Vascular by 28.3% during the 4th quarter. Advisor Group Inc. now owns 7,033 shares of the medical instruments supplier’s stock valued at $223,000 after acquiring an additional 1,550 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of LeMaitre Vascular during the 3rd quarter valued at about $235,000. MetLife Investment Advisors LLC acquired a new position in shares of LeMaitre Vascular during the 4th quarter valued at about $244,000. Finally, First Mercantile Trust Co. increased its stake in shares of LeMaitre Vascular by 74.0% during the 4th quarter. First Mercantile Trust Co. now owns 8,436 shares of the medical instruments supplier’s stock valued at $269,000 after acquiring an additional 3,587 shares during the last quarter. Institutional investors own 72.78% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply